What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The FDA has been taking action against compounding pharmacies that are illegally preparing and selling compounded versions of GLP-1 receptor agonists like semaglutide (the active ingredient in Ozempic and Wegovy) and liraglutide (the active ingredient in Victoza and Saxenda).

Here's a breakdown of what's happening:

What the FDA is Concerned About:

• Compounding of a "Me-Too" Drug: The FDA's primary concern is that these compounded GLP-1s are often essentially identical to the already-approved, FDA-listed drugs. Under federal law, compounding pharmacies are generally not supposed to compound drugs that are exact copies of commercially available, FDA-approved products. This is meant to prevent pharmacies from essentially creating generic versions of drugs before their patents expire.
• Risk of Harm to Patients: The FDA has warned that compounded versions may not meet the same quality, safety, and efficacy standards as the FDA-approved drugs. This could lead to issues with:
  • Potency: The compounded drug might have too much or too little of the active ingredient.
  • Purity: There could be contaminants or impurities in the compounded product.
  • Sterility: Especially for injectable medications, lack of sterility can lead to serious infections.
  • Consistency: Batch-to-batch consistency might not be guaranteed.
• Circumventing FDA Approval Process: The FDA-approved drugs have undergone rigorous clinical trials to demonstrate their safety and effectiveness. Compounded versions bypass this process.
• Misleading Marketing: Some pharmacies have been accused of marketing these compounded drugs as "FDA-approved" or implying they are equivalent to the branded medications, which is misleading.

FDA Actions:

The FDA has sent warning letters to compounding pharmacies and has indicated they will continue to monitor and take action against those violating federal laws. They have also issued public statements and consumer alerts to raise awareness.

Who is Still Operating Legally?

This is a complex and evolving situation, but generally, compounding pharmacies can legally operate if they are:

1. Compounding drugs that are NOT identical to commercially available, FDA-approved drugs. This often involves:

   • Making changes to the active ingredient: For example, using a different salt form of semaglutide or a different chemical structure that is not identical.
   • Making changes to the dosage form: For example, creating a topical version or a different oral formulation.
   • Compounding for a specific patient's needs: This must be based on a valid prescription from a healthcare practitioner for an individual patient with a documented medical need that cannot be met by an FDA-approved drug.

2. Operating within the scope of federal and state pharmacy laws.

Specific Brands/Services:

It's difficult to definitively list "who is still operating legally" because the landscape changes rapidly, and the legality often hinges on the specific formulation and prescribing situation. However, here are some general points:

• FDA-Approved GLP-1s: The most legally and reliably operating entities are the brand-name manufacturers themselves. These include:

  • Novo Nordisk: The manufacturer of Ozempic, Wegovy, and Victoza. These are the FDA-approved, rigorously tested products.
  • Eli Lilly and Company: The manufacturer of Mounjaro (tirzepatide) and Trulicity (dulaglutide), both FDA-approved GLP-1 receptor agonists.

• Compounding Pharmacies - The Nuance:

  • Many compounding pharmacies that were previously offering semaglutide or liraglutide in a way that closely mirrored the FDA-approved drugs have ceased these preparations due to FDA scrutiny.
  • Some compounding pharmacies may still be legally operating by preparing formulations that are demonstrably different from the FDA-approved versions. This could involve different inactive ingredients, different routes of administration (though injectable is still common), or unique combinations. However, the scientific evidence for the efficacy and safety of these significantly altered formulations might not be as robust as for the FDA-approved drugs.
  • It is crucial for consumers to be extremely cautious and to have a direct conversation with their prescribing doctor and the compounding pharmacy about the exact formulation being provided.

Key Takeaway for Consumers:

• Prioritize FDA-Approved Medications: For the vast majority of patients, the safest and most reliable option is to get an FDA-approved GLP-1 medication prescribed by their doctor.
• Be Wary of Compounded GLP-1s: If your doctor is considering a compounded GLP-1, ask them specific questions:
  • "What makes this compounded version different from the FDA-approved drug?"
  • "What evidence do you have for the safety and effectiveness of this specific compounded formulation?"
  • "Which compounding pharmacy is preparing this, and what are their quality control measures?"
• Consult Your Doctor: Always discuss any treatment options, including compounded medications, with your healthcare provider. They can help you weigh the risks and benefits and ensure you are receiving the best and safest care for your individual needs.

The FDA's actions are aimed at protecting public health, and it's essential for consumers to be informed and to seek treatments that have undergone the necessary regulatory review.